更新于：2024-11-01
EGb-761
更新于：2024-11-01
概要
基本信息
在研机构 |
最高研发阶段批准上市 |
首次获批日期 法国 (2002-02-28), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构
分子式C11H13ClN2S |
InChIKeyLAZPBGZRMVRFKY-HNCPQSOCSA-N |
CAS号16595-80-5 |
关联
16
项与 EGb-761 相关的临床试验The effectiveness of EGB761 in preventing permanent threshold shift : A randomized controlled trial.
An Observational, Open Label, Post Marketing Study to Evaluate the Safety and Effectiveness of Hoat Huyet Nhat Nhat Compared With Gingko Biloba EGb761 (Tanakan 40mg) in Patients With Symptoms Related to the Insufficient Blood Supply to the Brain
Non-interventional Prospective Observational Study to Describe EGB 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders.
100 项与 EGb-761 相关的临床结果
登录后查看更多信息
100 项与 EGb-761 相关的转化医学
登录后查看更多信息
100 项与 EGb-761 相关的专利（医药）
登录后查看更多信息
964
项与 EGb-761 相关的文献（医药）2024-12-01Current Neuropharmacology
Ginkgo biloba for Tardive Dyskinesia and Plasma MnSOD Activity: Association with MnSOD Ala-9Val Variant: A Randomized, Double-blind Trial
Article
作者: Tian, Yang ; Chen, Dachun ; Zhang, Xiang-Yang ; Wang, Li ; Zhu, Rongrong ; Wang, Dongmei ; Chen, Jiajing ; Kosten, Thomas R. ; Li, Jiaxin ; Zhou, Huixia
Background::
Excessive free radicals are implicated in the pathophysiology of tardive dyskinesia (TD), and Ginkgo biloba extract (EGb761) scavenges free radicals, thereby enhancing antioxidant enzymes such as mitochondrial manganese superoxide dismutase (MnSOD). This study examined whether EGb761 treatment would improve TD symptoms and increase MnSOD activity, particularly in TD patients with specific MnSOD Val-9Ala genotype.
Methods::
An EGb761 (240 mg/day) 12-week double-blind clinical trial with 157 TD patients was
randomized. The severity of TD was measured by the Abnormal Involuntary Movement Scale (AIMS)
and plasma MnSOD activity was assayed before and after 12 weeks of treatment. Further, in an expanded sample, we compared MnSOD activity in 159 TD, 227 non-TD and 280 healthy controls, as
well as the allele frequencies and genotypes for the MnSOD Ala-9Val polymorphism in 352 TD, 486
non-TD and 1150 healthy controls.
Results::
EGb761 significantly reduced TD symptoms and increased MnSOD activity in TD patients
compared to placebo (both p <.01). Moreover, we found an interaction between genotype and treatment
response (p <.001). Furthermore, in the EGb761 group, patients carrying the Ala allele displayed a significantly lower AIMS total score than patients with the Val/Val genotype. In addition, MnSOD activity
was significantly lower at baseline in TD patients compared with healthy controls or non-TD patients.
Conclusion::
EGb761 treatment enhanced low MnSOD activity in TD patients and produced greater
improvement in TD symptoms in patients with the Ala allele of the MnSOD Ala-9Val polymorphism.
2024-10-01Biological trace element research
Ginkgo Biloba Extract Can Antagonize Subchronic Arsenite Exposure-Induced Hepatocyte Senescence by Inhibiting Oxidative Damage and Inflammation in Rats
Article
作者: Zhang, Aihua ; Chen, Xiong ; Wu, Fan ; Ren, Qian ; Chen, Cheng
A growing body of evidence suggests that long-term arsenic exposure can induce liver injury. Our previous studies have demonstrated that liver injury occurs in arsenic-poisoning patients and arsenic-exposed rats. However, therapeutic targets are still unclear, and there is a lack of effective drugs. This study aimed to investigate the effects of sodium arsenite (arsenite) exposure on hepatocyte senescence and the intervention effect of ginkgo biloba extract in rats. In this study, 24 male Sprague-Dawley rats (weighing 180-200 g) were randomized into three groups. The control group received a normal diet, and the arsenic-exposed group was given 10 mg/L arsenite for 3 months by free drinking along with a normal diet. The ginkgo biloba extract treatment group was consecutively administered EGb761 (10 mg/kg, by gavage) for 1 month following 2 months of arsenite exposure. Our results showed that exposure to 10 mg/L arsenite induced narrowing of the hepatic sinus space, enlargement of hepatocytes, and increased multinucleated hepatocytes and inflammatory cell infiltration in rat liver tissue compared with the normal control group. Moreover, 10 mg/L arsenite also caused abnormal expression of inflammation-related indices (IL1-β, IL-6, TNF-α), oxidative damage-related indices (SOD, MDA, GPx), and senescence-related proteins (p16, p-p53, E2F1). EGb761 could effectively reduce the pathological damage of liver tissue and antagonize the abnormal expression of liver tissue inflammation and oxidative damage-related indices as well as cellular senescence-related proteins caused by arsenite exposure. Notably, EGb761 reduced the accumulation of arsenic in rat liver tissues. These results suggested that EGb761 could effectively alleviate subchronic arsenic exposure-induced senescence of hepatocytes, which may be achieved partially through inhibiting inflammation and oxidative damage in rats. This study may provide a new therapeutic target for arsenic-induced liver injury.
2024-10-01PLANTA MEDICA
Substantial Differences in Proanthocyanidin Contents among Ginkgo biloba Leaf Extracts in Herbal Medicinal Products Obtained from the German Market
Article
作者: Ritter, Thomas ; Wurglics, Mario ; Germer, Stefan
Abstract:
Pharmacologic activity of proanthocyanidins in Ginkgo biloba leaf extract has recently been reported. The objective of the present study was to screen proanthocyanidin contents in herbal medicinal products containing Ginkgo extracts. A recently published HPLC method for quantification of proanthocyanidins in G. biloba leaf extract EGb 761 was adopted to also be suitable for finished herbal medicinal products. The method was applied to 14 products from the German market. For each product, a set of three individual batches was purchased and analyzed. Substantial differences in proanthocyanidins contents were found among distinct products, ranging from 0.30 to 5.86%. The batch-to-batch variability within each product was low. The highest concentrations are in a similar range as, for example, the amount of Ginkgo terpene trilactones specified in the monograph for G. biloba leaf extract in the European Pharmacopeia. Although it has not yet been
established whether and to what extent proanthocyanidins contribute to the overall pharmacological or clinical efficacy of Ginkgo extracts, a potential impact on the purported benefits of different contents in proanthocyanidins cannot be ruled out. Quality assessment of different Ginkgo extracts in the future may include proanthocyanidins.
1
项与 EGb-761 相关的新闻（医药）100 项与 EGb-761 相关的药物交易
登录后查看更多信息
研发状态
批准上市
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 认知功能障碍 | 临床3期 | 法国 | 2003-08-26 | |
| 复发-缓解型多发性硬化 | 临床3期 | 法国 | 2003-08-26 | |
| 缺血性卒中 | 临床3期 | 捷克 | 2003-02-01 | |
| 缺血性卒中 | 临床3期 | 波兰 | 2003-02-01 | |
| 缺血性卒中 | 临床3期 | 罗马尼亚 | 2003-02-01 | |
| 缺血性卒中 | 临床3期 | 俄罗斯 | 2003-02-01 | |
| 神经损伤 | 临床3期 | 捷克 | 2003-02-01 | |
| 神经损伤 | 临床3期 | 波兰 | 2003-02-01 | |
| 神经损伤 | 临床3期 | 罗马尼亚 | 2003-02-01 | |
| 神经损伤 | 临床3期 | 俄罗斯 | 2003-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 204 | (EGb761®) | 積淵積製遞襯蓋鹽願鏇(範築遞衊衊廠壓鬱齋遞) = 顧顧鹽餘鹹廠鏇鏇積衊 蓋願顧蓋簾糧齋鏇範積 (簾壓選鏇壓淵齋積鹽獵, 網廠鏇構築簾憲夢艱顧 ~ 繭鹹鑰齋衊獵艱遞鬱積) 更多 | - | 2018-02-19 | ||
Placebo+Acetylsalicylic acid (Placebo) | 積淵積製遞襯蓋鹽願鏇(範築遞衊衊廠壓鬱齋遞) = 網願醖廠鑰齋簾鬱網衊 蓋願顧蓋簾糧齋鏇範積 (簾壓選鏇壓淵齋積鹽獵, 鏇襯餘獵願簾願鬱選範 ~ 鹹鹹選繭淵齋簾壓鑰獵) 更多 | ||||||
临床2期 | 22 | (EGb 761® 120 mg) | 鏇繭鹹顧獵艱窪繭鹹顧(糧願齋鹽獵窪襯築選廠) = 夢範選積壓夢鹹膚膚艱 膚築繭遞製淵鬱蓋鹽齋 (廠窪醖壓獵簾窪遞鏇遞, 製鹹夢願繭艱鏇廠鑰憲 ~ 憲鏇窪鏇築蓋積餘簾遞) 更多 | - | 2013-05-21 | ||
Placebo (Placebo) | 鏇繭鹹顧獵艱窪繭鹹顧(糧願齋鹽獵窪襯築選廠) = 糧製齋築憲積憲鏇廠糧 膚築繭遞製淵鬱蓋鹽齋 (廠窪醖壓獵簾窪遞鏇遞, 簾簾積齋積鏇製構遞襯 ~ 餘膚網範遞觸淵觸鑰憲) 更多 | ||||||
临床3期 | 3,069 | (Ginkgo Biloba) | 淵蓋鑰醖壓觸餘窪築廠(願淵獵鹹鬱餘襯膚淵鑰) = 衊醖膚鏇糧窪選觸襯觸 餘糧選顧窪鹽鏇願膚觸 (廠顧鑰選製淵憲鹹選鏇, 衊鑰鑰願積鬱蓋範鏇窪 ~ 鬱製網選顧襯衊醖艱艱) 更多 | - | 2010-09-16 | ||
Placebo (Placebo) | 淵蓋鑰醖壓觸餘窪築廠(願淵獵鹹鬱餘襯膚淵鑰) = 淵鏇膚糧廠製網繭築鏇 餘糧選顧窪鹽鏇願膚觸 (廠顧鑰選製淵憲鹹選鏇, 淵範鑰構夢鬱選壓糧醖 ~ 衊鑰網淵遞艱襯齋醖積) 更多 | ||||||
N/A | 410 | Ginkgo biloba extract EGb 761® 240 mg | 窪蓋選淵憲糧窪網鏇顧(鬱膚夢構壓顧遞鑰膚鹽) = 製糧積鹹遞淵製淵鬱繭 獵衊艱築網獵願衊憲構 (鬱艱醖鬱選淵獵積鹹夢 ) 更多 | 积极 | 2008-07-01 | ||
Placebo | 窪蓋選淵憲糧窪網鏇顧(鬱膚夢構壓顧遞鑰膚鹽) = 襯窪鑰衊壓願顧構醖顧 獵衊艱築網獵願衊憲構 (鬱艱醖鬱選淵獵積鹹夢 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用